Health Care • Biotechnology: Pharmaceutical Preparations
$14.46 ▼ -1.31
(-8.31%)
MKT CAP: $2.02B • VOL: 1.17M
52W L $11 52W H $23
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$12
MEDIAN
$16
MEAN
$16
HIGH
$20
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE GENB TAPE
GENB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $17.50 | $16.63 | 2025-02-14 | $13.16 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $18.22 | $17.06 | 2025-02-06 | $13.59 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $16.48 | $15.91 | 2025-01-29 | $13.88 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $14.75 | — | 2025-01-17 | $14.17 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $12.72 | $13.74 | 2025-01-09 | $12.87 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $17.21 | $15.04 | 2024-12-18 | $12.58 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $14.03 | $14.60 | 2024-12-04 | $13.45 | -4.3% | 48% | C |